Drug Profile
Oliceridine - Trevena
Alternative Names: OLINVO; OLINVYK; TRV 130A; TRV-130Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Trevena
- Developer Jiangsu Nhwa Pharmaceutical; Trevena
- Class Amines; Analgesics; Pyridines; Small molecules; Spiro compounds; Thiophenes
- Mechanism of Action Opioid mu receptor agonists; Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Acute pain
- Phase I Respiratory tract disorders
Most Recent Events
- 19 Apr 2024 Oliceridine - Trevena is available for licensing as of 19 Apr 2024. https://www.trevena.com/
- 19 Apr 2024 Trevena has patent protection for composition and methods of use of oliceridine in Brazil and Canada
- 04 Dec 2023 Trevena entered into national group purchasing agreement with Premier for oliceridine (OLINVYK)